Molecular Testing: The Game Changer for Thyroid Nodules
Molecular Testing: The Game Changer for Thyroid Nodules
Why It Matters
Molecular testing is transforming how thyroid nodules are evaluated, offering a clearer path forward for patients.
Contents
What is Molecular Testing?
Molecular testing analyzes the genetic material in thyroid nodules to assess cancer risk. This advanced testing can identify mutations and gene expressions that indicate whether a nodule is likely benign or malignant. It's a crucial tool that helps doctors decide if surgery is necessary.
Types of Molecular Tests
There are several types of molecular tests available, each with unique benefits. For example, ThyroSeq v3 assesses a large number of genetic alterations, while Afirma GSC uses genomic sequencing to classify nodules. These tests have high negative predictive values, making them effective in ruling out cancer.
When is Molecular Testing Used?
Molecular testing is often used after an initial FNA shows indeterminate results. It helps refine the diagnosis by providing additional information about the nodule's risk of cancer. The decision to use these tests depends on availability and the specific characteristics of the nodule.
FAQs
What does molecular testing detect?
It detects genetic mutations linked to cancer.
How accurate is molecular testing?
It has a high negative predictive value, effectively ruling out cancer.
What are common molecular tests?
ThyroSeq v3 and Afirma GSC are widely used.
Is molecular testing always needed?
It's often used when FNA results are indeterminate.
Wrapping Up
Molecular testing provides vital insights, reducing unnecessary surgeries.
Additional References
- Steward DL, et al. Performance of a Multigene Genomic Classifier in Thyroid Nodules.
- Nikiforova MN, et al. Analytical performance of the ThyroSeq v3 genomic classifier.
This article has been reviewed for accuracy by one of the licensed medical doctors working for Doctronic.